company background image
LAB logo

Standard BioTools NasdaqGS:LAB Stock Report

Last Price

US$2.71

Market Cap

US$1.0b

7D

0.4%

1Y

36.2%

Updated

28 Mar, 2024

Data

Company Financials +

Standard BioTools Inc.

NasdaqGS:LAB Stock Report

Market Cap: US$1.0b

LAB Stock Overview

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

LAB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Standard BioTools Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Standard BioTools
Historical stock prices
Current Share PriceUS$2.71
52 Week HighUS$3.16
52 Week LowUS$1.46
Beta1.63
1 Month Change15.81%
3 Month Change22.62%
1 Year Change36.18%
3 Year Change-42.58%
5 Year Change-79.14%
Change since IPO-80.67%

Recent News & Updates

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Feb 17
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Recent updates

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Feb 17
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Jan 12
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Aug 13
Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Fluidigm Corporation: Investment Opportunity

Jan 26

Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Dec 15
Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Jul 27
Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

Jun 20

Fluidigm gains after report that activist takes 11% stake, may push for unit sale

May 11

Fluidigm Corporation 2021 Q1 - Results - Earnings Call Presentation

May 07

Fluidigm Corporation (NASDAQ:FLDM) Analysts Just Slashed This Year's Estimates

Feb 15
Fluidigm Corporation (NASDAQ:FLDM) Analysts Just Slashed This Year's Estimates

Shareholder Returns

LABUS Life SciencesUS Market
7D0.4%-0.2%0.4%
1Y36.2%4.5%28.8%

Return vs Industry: LAB exceeded the US Life Sciences industry which returned 4.5% over the past year.

Return vs Market: LAB exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is LAB's price volatile compared to industry and market?
LAB volatility
LAB Average Weekly Movement9.4%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: LAB's share price has been volatile over the past 3 months.

Volatility Over Time: LAB's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999537Michael Egholmhttps://www.standardbio.com

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

Standard BioTools Inc. Fundamentals Summary

How do Standard BioTools's earnings and revenue compare to its market cap?
LAB fundamental statistics
Market capUS$1.03b
Earnings (TTM)-US$74.66m
Revenue (TTM)US$106.34m

9.8x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LAB income statement (TTM)
RevenueUS$106.34m
Cost of RevenueUS$55.89m
Gross ProfitUS$50.45m
Other ExpensesUS$125.11m
Earnings-US$74.66m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin47.44%
Net Profit Margin-70.21%
Debt/Equity Ratio38.9%

How did LAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.